1. Home
  2. NAMS vs FORM Comparison

NAMS vs FORM Comparison

Compare NAMS & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • FORM
  • Stock Information
  • Founded
  • NAMS 2019
  • FORM 1993
  • Country
  • NAMS Netherlands
  • FORM United States
  • Employees
  • NAMS N/A
  • FORM N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • FORM Semiconductors
  • Sector
  • NAMS Health Care
  • FORM Technology
  • Exchange
  • NAMS Nasdaq
  • FORM Nasdaq
  • Market Cap
  • NAMS 3.1B
  • FORM 3.0B
  • IPO Year
  • NAMS N/A
  • FORM N/A
  • Fundamental
  • Price
  • NAMS $38.74
  • FORM $57.26
  • Analyst Decision
  • NAMS Strong Buy
  • FORM Buy
  • Analyst Count
  • NAMS 10
  • FORM 8
  • Target Price
  • NAMS $43.70
  • FORM $48.57
  • AVG Volume (30 Days)
  • NAMS 1.3M
  • FORM 1.3M
  • Earning Date
  • NAMS 11-06-2025
  • FORM 10-29-2025
  • Dividend Yield
  • NAMS N/A
  • FORM N/A
  • EPS Growth
  • NAMS N/A
  • FORM N/A
  • EPS
  • NAMS N/A
  • FORM 0.53
  • Revenue
  • NAMS $64,006,000.00
  • FORM $759,313,000.00
  • Revenue This Year
  • NAMS N/A
  • FORM $2.58
  • Revenue Next Year
  • NAMS N/A
  • FORM $7.33
  • P/E Ratio
  • NAMS N/A
  • FORM $112.08
  • Revenue Growth
  • NAMS 762.15
  • FORM 2.29
  • 52 Week Low
  • NAMS $14.06
  • FORM $22.58
  • 52 Week High
  • NAMS $41.47
  • FORM $61.10
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 66.43
  • FORM 76.31
  • Support Level
  • NAMS $35.50
  • FORM $41.84
  • Resistance Level
  • NAMS $39.03
  • FORM $61.10
  • Average True Range (ATR)
  • NAMS 2.30
  • FORM 2.50
  • MACD
  • NAMS -0.16
  • FORM 1.35
  • Stochastic Oscillator
  • NAMS 61.67
  • FORM 83.29

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About FORM FormFactor Inc. FormFactor Inc.

FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.

Share on Social Networks: